Smoking is a common risk factor for many diseases 1 . We conducted genome-wide association meta-analyses for the number of cigarettes smoked per day (CPD) in smokers (n = 31,266) and smoking initiation (n = 46,481) using samples from the ENGAGE Consortium. In a second stage, we tested selected SNPs with in silico replication in the Tobacco and Genetics (TAG) and Glaxo Smith Kline (Ox-GSK) consortia cohorts (n = 45,691 smokers) and assessed some of those in a third sample of European ancestry (n = 9,040). Smoking behavior and nicotine dependence are considered to be influenced by genetics 5 . Although environmental influences play a strong role in the initiation of smoking 6 , the heritability of smoking persistence, smoking quantity and nicotine dependence has been high in most twin studies 6, 7 . Sequence variants within a cluster of genes on chromosome 15q25 that encode nicotinic acetylcholine receptors (nAChRs) have recently been shown to associate with CPD 8,9 , nicotine dependence 3,8 and smoking-related diseases such as lung cancer 8, 10, 11 , peripheral arterial disease (PAD) 8 and chronic obstructive pulmonary disease (COPD) 12 .
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Smoking is a common risk factor for many diseases 1 . We conducted genome-wide association meta-analyses for the number of cigarettes smoked per day (CPD) in smokers (n = 31,266) and smoking initiation (n = 46,481) using samples from the ENGAGE Consortium. In a second stage, we tested selected SNPs with in silico replication in the Tobacco and Genetics (TAG) and Glaxo Smith Kline (Ox-GSK) consortia cohorts (n = 45,691 smokers) and assessed some of those in a third sample of European ancestry (n = 9,040). Variants in three genomic regions associated with CPD (P < Smoking behavior and nicotine dependence are considered to be influenced by genetics 5 . Although environmental influences play a strong role in the initiation of smoking 6 , the heritability of smoking persistence, smoking quantity and nicotine dependence has been high in most twin studies 6, 7 . Sequence variants within a cluster of genes on chromosome 15q25 that encode nicotinic acetylcholine receptors (nAChRs) have recently been shown to associate with CPD 8, 9 , nicotine dependence 3, 8 and smoking-related diseases such as lung cancer 8, 10, 11 , peripheral arterial disease (PAD) 8 and chronic obstructive pulmonary disease (COPD) 12 .
To search for additional common variants associated with smoking behavior, we performed meta-analyses of genome-wide association (GWA) studies, mainly using samples of European ancestry from the ENGAGE consortium (see URLs) and focusing on two smoking phenotypes: CPD and smoking initiation. The smoking initiation analysis was performed with a total of 30,431 ever-smokers and 16,050 never-smokers, using data from 12 GWA studies: Corogene, deCODE, Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior l e t t e r s
The Estonian Genome Project of University of Tartu (EGPUT), the Erasmus Rucphen Family study (ERF), the Northern Finland Birth Cohorts (NFBC), the KORA study (Kooperative Gesundheitsforschung in der Region Augsburg), the Netherlands Twin Registry and Netherlands Study of Depression and Anxiety (NTR-NESDA), the Rotterdam study, the Sorbs study, the United Kingdom Twin Study (TwinUK) and the Wellcome Trust Case Controls Consortium Study of Coronary Heart Disease (WTCCC-CAD). For CPD, we combined data from these same 12 GWA studies, plus subjects from the Nijmegen Lung and Bladder Cancer sample (NL-BLC) study, for a total of 31,266 subjects. Information on the meta-analysis studies for CPD and smoking initiation is provided in Supplementary Table 1, the Supplementary Note and in the Online Methods. After genomic control correction of each component study, we combined association data for ~2,500,000 imputed and genotyped autosomal SNPs with a fixed-effects additive meta-analysis using the inverse-variance method for CPD and smoking initiation. Quantile-quantile plots for CPD, excluding markers in the 15q25 region, displayed only modest inflation of the χ 2 -test statistic (genomic control inflation factor (λ GC ) = 1.02) ( Supplementary  Fig. 1a) . In addition to the 15q25 locus, SNPs at two loci, 19q13 and 7p14, were genome-wide significant (GWS) for CPD (P < 5 × 10 −8 ) in the meta-analysis data. The quantile-quantile plot for smoking initiation displayed weak inflation of the χ 2 -test statistic (λ GC = 1.03) and no GWS associations (Supplementary Fig. 1b) .
We selected 15 regions for smoking initiation totaling 277 SNPs and 14 regions for CPD totaling 443 SNPs for in silico replication in samples from the TAG and the Ox-GSK consortia (see accompanying papers published in this issue 13, 14 ) (Supplementary Table 2 ). For CPD, we included a region on chromosome 8p11 on the basis of (i) its large number of SNPs showing suggestive associations with CPD, (ii) the strong candidacy of genes in the region (CHRNA6 and CHRNAB3, encoding nAChR subunits α6 and β3) and (iii) previous suggestive evidence for association between SNPs within this region and nicotine dependence 2, 3 .
In addition to the 15q25 locus, three new loci, 7p14, 8p11 and 19q13, were found to be GWS for CPD after combining the results from the ENGAGE meta-analysis set with those of TAG and Ox-GSK (Fig. 1 Table 2 ).
For further confirmation of the CPD association signals at the 7p14, 8p11 and 19q13 loci, selected markers from these regions were genotyped in additional samples (n = 9,040) from Iceland, Australia, Denmark, Germany and Spain ( Table 1) . The markers at 8p11 and at the 19q13 loci had effects in the same direction but the marker on 7p14 did not ( Table 1) . After combining these data with ENGAGE results and the in silico replication, the 8p11 and the 19q13 loci remained GWS but the 7p14 locus did not ( Table 1) . The CPD association results for the SNPs in Table 1 for each study are presented in Supplementary Table 3 and Supplementary Figure 2 .
Nominally significant heterogeneity in the strength of association with CPD was observed for rs1051730 at 15q25 (P = 0.035, fraction of variation due to heterogeneity (I 2 ) = 32%) and rs215614 at 7p14 (P = 0.018, I 2 = 34%). Given previous and current evidence, it is highly likely that there is a true association between 15q25 and CPD. Therefore, its heterogeneity must be due to differences between the study populations used, such as different CPD information ascertainment, different types of cigarettes being used, different phenotypic and demographic ascertainment strategies or different genetic structures. The heterogeneity observed at 7p14 could be caused by a false positive finding or, if it is indeed a true positive, some combination of the 'winner's curse', which inflates initial effect estimates, and the same sort of differences driving the heterogeneity at 15q25.
The strongest associations observed with CPD in the combined analysis were with SNPs within the previously identified region on chromosome 15q25 (rs1051730[A], P = 2.4 × 10 −69 , effect size = 0.80 CPD) ( Fig. 1 and Table 1 ). We searched for additional association signals in the 15q25 region which were not accounted for by rs1051730 by performing linear regression using the rs1051730 allele count as a covariate in a subset of the ENGAGE samples (n = 23,089). The residual signals were mostly tagged by two SNPs in relatively low linkage disequilibrium (LD), rs2869046[T] (P = 4.8 × 10 −5 , effect size = 0.5) and rs2036534[T] (P = 9.1 × 10 −5 , effect size = 0.50 CPD) (r 2 = 0.080 and D′ = 0.65 in the HapMap CEU samples) (Supplementary Fig. 3 ). These two SNPs are also in fairly weak LD with rs1051730 (r 2 = 0.12, D′ = 0.49 and r 2 = 0.18, D′ = 1.05 in the HapMap CEU samples for rs2869046 and rs2036534, respectively). These data suggest that either the three variants Results are given for the ENGAGE analysis, the in silico replication obtained by combining results from TAG and Ox-GSK and the results of single-SNP assay replications in samples from Iceland, Australia, Denmark, Germany and Spain (ISL-AUST-DEN-GER-SPA). Samples that were both in ENGAGE and either TAG or Ox-GSK were removed before obtaining the combined in silico results. Shown are the number of smokers (n), the effect allele and the other allele, the allele frequencies (freq.), the chromosome number (chr.) and position, the estimated allelic effects on CPD and their standard errors in CPD (effect and s.e.m.), the P value for the test of association, the P value for the test for heterogeneity in effect size (P het ) and an estimate of the proportion of total variation in study estimates that is due to heterogeneity (I 2 ).
a Meta-analysis, n = 31,266. b In silico replication, n = 45,691. c Direct genotyping, n = 9,040. d n = 85,997.
HapMap CEU samples) was previously reported to associate with nicotine dependence to an extent that could not be accounted for by rs1051730 15 . As with rs2036534, rs578776 is in weak LD with rs1051730 (r 2 = 0.21, D′ = 1.0 in the HapMap CEU samples). However, rs578776 is not correlated with rs2869046 (r 2 = 0.038, D′ = 0.41 in the HapMap CEU samples) and thus does not explain the signal described here for rs2869046 at the 15q25 locus (Supplementary Fig. 3 ).
The SNPs on chromosome 8p11 that reached genome-wide significance in the HapMap CEU samples, rs6474412 (effect size = 0.29 CPD, P = 1.4 × 10 −8 ) and rs13280604 (effect size = 0.31 CPD, P = 1.3 × 10 −8 ), are in perfect LD with a variant (rs13277254 [T] ) that was previously highlighted as being suggestively associated in a GWA study of nicotine dependence using controls who smoked but had not developed nicotine dependence (rs13277254[T], OR = 1.19, P = 6 × 10 −5 ) 2,3 . The other SNPs in the region showing association with CPD ( Fig. 1) are all in strong LD with these two SNPs. rs6474412 is located about 2.1 kb from the 5′ end of CHRNB3, the gene encoding the β3 nAChR subunit, and belongs to a group of highly correlated SNPs that includes two SNPs in exons of CHRNB3: a synonymous SNP (rs4593) and a nonsynonymous SNP (rs4952) 3 . Although CHRNB3 is implicated by its proximity to the location of the associating SNPs, these markers could be tagging variation elsewhere within the LD block that also contains CHRNA6 (encoding the α6 nAChR subunit) (Fig. 1) .
Nine different nicotinic cholinergic receptor subunits (α2-α7 and β2-β4) are expressed in the human brain and they combine with each other in diverse patterns to form various types of functional pentameric receptors distinguished by subunit composition and sensitivity to nicotine 16 . Rodent studies have implicated CHRNA6 and CHRNB3 receptor subunits in nicotineinduced dopamine release 17 . Neither CHRNA6 nor CHRNB3 are expressed in lung tissue 18 .
The CPD-associated markers on chromosome 19q13 are located in a region harboring CYP2A6, which encodes CYP2A6, an enzyme that plays a major role in the oxidation of nicotine in human liver microsomes; this region also harbors several other genes and pseudogenes belonging to the CYP gene family (Fig. 1) . Several sequence variants in or near CYP2A6 that reduce CYP2A6's enzymatic activity have been identified 4 . For some of these variants, effects on smoking behavior have been suggested 4 . In the present study, the most significant association in the region was observed with rs4105144. This SNP is in LD with CYP2A6*2 (rs1801272) (r 2 = 0.13 and D′ = 1.0 in the HapMap CEU samples) and the CYP2A6*2 reduced-function allele is only found on the background of rs4105144 [C] , which associates with reduced smoking quantity. Although the effect of rs4105144 (effect size ± s.e.m.) (0.39 ± 0.06 CPD) is smaller than that of rs1801272 (0.68 ± 0.18 CPD) ( Table 1) , its association is more significant (that is, a lower P value) because of higher minor allele frequency. This suggests that rs4105144[C] may be tagging many reduced-function variants. The second most significant association in the region was with rs7937, in the untranslated 3′ end of RAB4B, which is in LD with rs4105144 (r 2 = 0.32, D′ = 0.82 in the HapMap CEU samples). The third most significant association in the region was with rs7260329, which is almost independent of rs4105144 (r 2 = 0.0064, D′ = 0.091 in the HapMap CEU samples). rs7260329 is an intronic SNP in CYP2B6, but the product of this gene converts nicotine to cotinine with about 10% of the catalytic activity of the CYP2A6 enzyme; this product also metabolizes several drugs of abuse, as well as bupropion, an atypical antidepressant also used as a smoking cessation aid 4 . The CYP2B6 levels in the human brain are higher than those of CYP2A6 and are altered in smokers and alcoholics 4, 19 .
One of the ENGAGE studies (GenMetS) contained information on immune-reactive serum cotinine levels for a set of samples (n = 485) 20 , which reflect the catalytic activity of the CYP2A and CYP2B gene products 4 . One of the SNPs associating with CPD at 19q13 (rs7937[G]) showed nominally significant association with cotinine levels (effect size = 1.16, P = 0.0031), whereas the markers at 8p11 and 7p14 did not associate with cotinine levels in this sample (P > 0.26). Two SNPs at 19q13, rs2233152[A] and rs2287692 [A] showed a stronger association with cotinine levels than rs7937 (effect size = 1.92, P = 0.00021); however, these two SNPs did not associate strongly with CPD in the ENGAGE samples (P = 0.013) and most of the markers showing the strongest association with CPD did not associate with cotinine levels.
We next assessed the SNPs from the newly identified regions associating with CPD for association with nicotine dependence, defined Table 4a ).
As we had previously found association of the 15q25 region with lung cancer and PAD 8 , we directly genotyped selected markers from the 7p14, 8p11 and 19q13 regions for association with lung cancer (including 2,019 cases and 40,509 controls) and PAD (2,855 cases and 40,424 controls) in samples of European ancestry. The lung cancer data were also combined with summary-level data from the publicly available GWA dataset on lung cancer (2,518 cases and 1,921 controls) from the International Agency for Research on Cancer (IARC) 11 ( Table 2) Table 2) . Similar to the effect on CPD (Table 1) , the effects of these variants on lung cancer is substantially weaker than that of the 15q25 variants (OR = 1.31, P = 1.5 × 10 −8 ) 8, 10, 11 (Table 2) , warranting further analysis in additional sample sets. No significant associations with PAD were observed for the markers tested (Supplementary Table 4b) . The potential effect of rs7260329 [G] and rs4105144[C] on lung cancer is notable in light of the fact that the CYP2A6 gene product activates procarcinogenic nitrosamines 4 .
The 13 regions that were selected from the ENGAGE meta-analysis of CPD but did not reach GWS suggest a number of interesting functional candidate genes, including GABRA1 and GABRG2 (genes encoding γ-aminobutyric acid receptor subunits), as well as PDE1C, CDH13 and A2BP1, which were all highlighted in a previous GWA study of nicotine dependence and smoking cessation 21, 22 . Some of these genes may play a role in smoking behavior.
In conclusion, we have discovered sequence variants associated with smoking behavior within regions harboring nAChR genes (CHRNB3-CHRNA6, 8p11) and nicotine-metabolizing enzyme genes (CYP2A6-CYP2B6, 19q13). The 8p11 association is reminiscent of that with chromosome 15q25; both regions contain genes encoding nAChRs, and the key variants in each region associate with nicotine dependence and lung cancer, bringing up the question of whether the risk for lung cancer is through the effect on smoking behavior or whether it involves increased vulnerability to the harmful effects of smoking as well 8, [23] [24] [25] [26] [27] . However, the dissection of the causal Shown are the number of cases and controls (n), the frequencies of the effect allele (see table 1) in cases and controls, the odds ratio and 95% confidence intervals and the P value for the test of association. The results for PAD are shown in supplementary table 4.
a For IARC, results for rs6474412 and rs215614 were not available and here we report results for rs6474414 and rs215605, respectively, both of which are perfect surrogates in the HapMap CEU samples (r 2 = 1).
